Market revenue in 2023 | USD 776.7 million |
Market revenue in 2030 | USD 4,488.5 million |
Growth rate | 28.5% (CAGR from 2023 to 2030) |
Largest segment | Drug optimization & repurposing |
Fastest growing segment | Drug Optimization & Repurposing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Drug Optimization & Repurposing, Preclinical Testing |
Key market players worldwide | International Business Machines Corp, Exscientia PLC ADR, Alphabet Inc Class A, Benevolent AI, Recursion Pharmaceuticals Inc Class A, Aitia, BioSymetrics, Euretos, Berg, Atomwise, Insitro |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to artificial intelligence in drug discovery market will help companies and investors design strategic landscapes.
Drug optimization & repurposing was the largest segment with a revenue share of 53.73% in 2023. Horizon Databook has segmented the U.S. artificial intelligence in drug discovery market based on drug optimization & repurposing, preclinical testing covering the revenue growth of each sub-segment from 2018 to 2030.
Availability of developed infrastructure to facilitate the adoption of AI, coupled with the local presence of major players operating, is expected to contribute to market growth. In addition, growing awareness about AI and increasing number of manufacturers.
Adopting it to lower costs of drug discovery is expected to further support market growth in the U.S. In August 2017, BERG a biopharmaceutical company entered into a research collaboration with AstraZeneca to identify and evaluate novel therapeutics & targets for the treatment.
Parkinson’s disease using its AI platform, BERG Interrogative Biology. This research collaboration provided AstraZeneca with new and innovative ways of drug discovery approaches by using BERG’s AI platform.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. artificial intelligence in drug discovery market , including forecasts for subscribers. This country databook contains high-level insights into U.S. artificial intelligence in drug discovery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account